Table 2.
Plasma levels of factors of glucose and lipoprotein metabolism during 12-month trial in controls
| Treatment duration (week) | 0 | 4 | 12 | p valuesa |
|---|---|---|---|---|
| FPG (mg/dL) | 111 (94, 143)b | 142 (116, 168) | 124 (92, 164) | 0.0572 |
| HbA1c (%) | 6.3 (5.8, 12.3) | 7.0 (6.2, 7.3) | 7.0 (6.2, 7.6) | 0.0087 |
| C-peptide (ng/mL) | 5.2 (4.1, 10.5) | 6.2 (4.4, 7.3) | 7.2 (5.8, 9.5) | 0.8233 |
| TC (mg/dL) | 176 (132, 209) | 176 (142, 213) | 180 (149, 200) | 0.8948 |
| TG (mg/dL) | 109 (88, 156) | 139 (87, 177) | 115 (59, 141) | 0.0973 |
| LDL-C (mg/dL) | 105 (78, 125) | 96 (82, 134) | 94 (78, 126) | 0.8233 |
| HDL-C (mg/dL) | 36 (33, 44) | 40 (32, 43) | 42 (35, 51) | 0.1114 |
| RLP-C (mg/dL) | 6.7 (4.5, 12.1) | 9.7 (4.8, 13.1) | 6.9 (5.1, 12.6) | 0.4227 |
| Apo B (mg/dL) | 93 (71,117) | 102 (72, 101) | 89 (70, 117) | 0.7165 |
| Ox-LDL (U/L) | 81 (68, 101) | 86 (75, 97) | 81 (75, 105) | 0.8948 |
| LPL (ng/mL) | 79 (65, 90) | 67 (47, 86) | 66 (53, 89) | 1.0000 |
| LDL-C/apo B ratio | 1.12 (1.04, 1.23) | 1.12 (1.09) | 1.14 (1.11, 1.16) | 0.8948 |
apo B apolipoprotein B, C cholesterol, FPG fasting plasma glucose, HbA1c glycated hemoglobin A1c, HDL high-density lipoprotein, LDL low-density lipoprotein, LPL lipoprotein lipase, Ox oxidized, RLP remnant-like particle, TC total cholesterol, TG triglyceride
aStatistical significance by Friedman test; p < 0.05 was considered as significant
bMedian (25 and 75 percentile)